Detalhe da pesquisa
1.
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 382(13): 1232-1243, 2020 03 26.
Artigo
Inglês
| MEDLINE | ID: mdl-32212519
2.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130809
3.
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
AIDS
; 35(7): 1061-1072, 2021 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33946085
4.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lancet HIV
; 7(11): e740-e751, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33128903
5.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33136751
6.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lancet HIV
; 2(10): e427-37, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26423650
7.
Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis.
J Int AIDS Soc
; 17(4 Suppl 3): 19530, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25394039